Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

Class:IdLiteratureReference:9728525
_displayNameDapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
_timestamp2021-04-21 10:11:11
author[Person:5228432] Zhang, L
[Person:8877541] Feng, Y
[Person:9728547] List, J
[Person:9728494] Kasichayanula, S
[Person:9728526] Pfister, M
created[InstanceEdit:9728508] Jassal, Bijay, 2021-04-21
journalDiabetes Obes Metab
pages510-6
pubMedIdentifier20518806
titleDapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
volume12
year2010
(literatureReference)[Summation:9728530] The human gene SLC5A2 encodes sodium/glucose cotransporter 2...
[ChemicalDrug:9728168] dapagliflozin [extracellular region]
[Change default viewing format]
No pathways have been reviewed or authored by Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight (9728525)